The Leading Source of Diabetes Business News It's Complicated

Total Page:16

File Type:pdf, Size:1020Kb

The Leading Source of Diabetes Business News It's Complicated The Leading Source of Diabetes Business News It’s Complicated January/February 2011 • No. 105 The diabetes business used to be fairly straightforward. It’s a lot more complicated now, but that’s not a bad thing. Take insulin. After it was commercialized in the early 1920s, the goal was clear: sell more insulin. But look at today’s three major insulin makers: Eli Lilly, sanofi-aventis, and Novo Nordisk. For all three, to be sure, insulin is still preeminent. The diabetes divisions of Novo Nordisk and Lilly draw most of their revenue from human insulin and rapid-acting analogs, while sanofi-aventis’ blockbuster basal analog Lantus, as well as its mealtime insulins, continue to drive the bottom line. But all three companies have also developed (or are developing) GLP-1 analogs, Lilly has invested in oral drugs for type 2 diabetes (most recently through a major partnership with Boehringer Ingelheim), and the companies are also developing new therapeutic approaches for different stages of disease progression. The evolution of the insulin makers reflects broader industry trends. As our understanding of diabetes has expanded – and we dig deeper into the molecular complexities of the disease – it’s clear that single- focus large companies can no longer prosper. Ours is an era of individualized treatment that mixes and matches different drugs and technologies that try to meet the unique needs of every person with diabetes. Toward that end, companies are forming partnerships to find complementary therapies and development efforts that will create better, more streamlined options for patients. In this issue, for example, we report on Merck’s purchase of the glucose-dependent insulin company SmartCells; Roche’s acquisition of Marcadia and its dual GLP-1/GIP agonist; Abbott’s and Reata’s phase 2 results for their novel CKD treatment; XOMA’s and Servier’s collaboration for the anti- inflammatory drug candidate XOMA 052; Access Pharmaceuticals’ own oral insulin partnership with an undisclosed “major global pharmaceutical company”; sanofi-aventis’ collaboration with Harvard for translational research; GSK’s partnership to distribute Bioton’s human insulin in Russia; and AstraZeneca’s alliance with Evotec for beta cell regeneration. While these types of partnerships are hardly novel, the sheer number bodes well for more creative and ultimately effective therapies, including those for complications, for novel insulin formulations, and for earlier treatment of type 1 diabetes. Also in this issue, we speak to Dr. Sanjay Kaul, a noted cardiologist who’s on the FDA advisory panels for three weight-loss drug candidates – Qnexa, Lorqess, and Contrave. Dr. Kaul has given some of the strongest statements from anyone on the panel on the risk-benefit challenges for obesity medications. In our interview, he explains his wariness of REMS and post-approval efficacy studies, argues that clinical trial populations should reflect the comorbidities of the obese population at large, and voiced his view that a post-approval trial would be appropriate to assess Qnexa’s CV risk . We also summarize recent literature on obesity, which continues to generate significant academic interest even as the future for treatment therapies remains mixed. As we look ahead to another year, we hope that companies continue to collaborate, innovate, and persevere in their battle against these daunting public health challenges. Yours truly, Kelly L. Close Major Headlines Orexigen – Receives FDA complete response letter Requiring CV Outcomes Trial – page 8 Arena – Provides regulatory update; FDA requests more non-clinical studies – page 11 Amylin – FDA approves Bydureon tQT protocol; Byetta sales drop 17% – page 13 Vivus – May run retrospective study on topiramate teratogenicity – page 15 MannKind – Receives second complete response letter – page 17 Novartis – Gains new EU indication for Lucentis in diabetic macular edema – page 18 XOMA – Enters collaboration agreement with Servier for XOMA 052 – page 20 Valeritas – Receives 510(k) clearance for the V-Go; to launch in 2011 – page 32 Merck – Announces purchase of glucose-dependent insulin company SmartCells – page 34 Reata/Abbott – Release positive interim phase 2b results for CKD therapy – page 37 BMS/AZ – Receive FDA approval for Kombiglyze XR – page 40 Sanofi-aventis/Harvard – Collaborating for translational biomedical research – page 48 Diabetes Close Up #105 ~ January/February 2011 ~ It’s Complicated ~ www.closeconcerns.com 2 In This Issue 1. Quotable Quotes in Diabetes ..................................................................................................................... 6 2. diaTribe FingerSticks ................................................................................................................................ 7 3. DCU Company Watch ................................................................................................................................ 8 § Orexigen – Receives FDA complete response letter requiring CV outcomes trial for Contrave § Roche –Diabetes Care sales flat on year, down in 4Q10; taspoglutide and other drugs dropped § Pfizer – No mention of 11 diabetes compounds in pipeline in 4Q10 report § Eli Lilly – Humalog up 3.1% and Humulin up 5.5% in 4Q and 5% for year; teplizumab dropped § Novartis – Galvus franchise climbs; Lucentis approved for DME in the EU; pipeline shifts § AstraZeneca – Recognizes $32 million in Alliance Revenue for Onglyza § Arena – Provides regulatory update; FDA requests additional non-clinical studies § BMS – Onglyza ends 4Q10 with $73 million in sales; dapagliflozin MAA validated by EMA § Abbott– Diabetes Care up 1.5% for 4Q and 3% for full year; ~2-5% growth forecast for 2011 § Amylin – FDA approves Bydureon tQT protocol; Byetta sales drop 17%; Symlin sales grow 26% § J&J – Diabetes Care sales up 1.2% for 2010; US SMBG market share said to increase in Q4 § Amgen – Still no update on three diabetes compounds in development § Vivus – Reports on FDA meeting; may run retrospective study on topiramate teratogenicity § Diamyd Medical – Fully enrolls phase 3 US DiaPrevent; increased cash from OMJPI deal § FDA – Gives update on 510(k) changes, postpones decision on proposed class 2b § MannKind – Receives second complete response letter § Forest Laboratories – TTP399 glucokinase activator program to enter phase 2 trials in 1H11 § TransPharma – Renames transdermal drug delivery system ViaDor (formerly ViaDerm) § Novartis – Gains new EU indication for Lucentis in vision loss from diabetic macular edema § Lexicon – Announces positive clinical results for oral SGLT1/SGLT2 inhibitor LX4211 § ISIS – Adds obesity drug to metabolic pipeline; clarifies plans to launch chemistry 2.5 § XOMA – Enters collaboration with Servier for XOMA 052, announces phase 2a results § Zafgen – Announces topline results from phase 1b study for obesity drug candidate ZGN-433 § United Laboratories International Holding Limited (TUL) – China clears new insulins § GSK – Partners with Bioton to distribute human insulin in Russia § Novo Nordisk – Shares topline phase 3 data on Degludec/DegludecPlus; plans 2013 launches § Amylin/Eli Lilly – File sNDA for use of Byetta as an add-on to basal insulin § Takeda – Completes US patent litigation settlements for Actos and ACTOplus met § Abbott/FDA – Recall up to 359 million glucose test strips due to risk of falsely low results § Novo Nordisk – Partners for oral insulin licensing, Bangladeshi insulin manufacturing § Sanofi-aventis – Acquires worldwide rights to Ascendis' drug delivery platform for diabetes § Amylin – Starts filing metreleptin BLA in lipodystrophy-related diabetes, hypertriglyceridemia § Vivus – Applies for EU regulatory approval of Qnexa, replies to FDA complete response letter § Evotec/MedImmune/AstraZeneca – Partner for biologic beta cell regeneration program § Medtronic – Announces FDA approval and US launch of CareLink Pro 3.0 § WellDoc – Announces integration of DiabetesManager with electronic health records § Living Cell Technologies – Receives approval to market DIABECELL in Russia § Biodel – Plans to select a new Linjeta formulation to pursue by F1H11; pump data announced § Satiety – Launches TOGA procedure in the UK through the Nuffield Health Leeds Hospital § Orexigen – Discusses positive advisory committee vote for Contrave § Valeritas – Receives 510(k) clearance for the V-Go; to launch in 2011 § Access Pharmaceuticals – Partners with "major" company to test its oral insulin candidate § Allergan – FDA panel votes in favor of expanding LAP-BAND indication § Merck – Announces agreement to acquire SmartCells, develop glucose-dependent insulin § GSK – Drops development of SRT501 to focus on more potent SIRT1 activators § Sanofi-aventis – Announces plans to launch reusable insulin pen in India in 2Q11 § Novo Nordisk – Releases PK/PD data on coadministration of Victoza and Levemir § D. Medical – Revenue recognition hiccups; looking toward emerging market launch in 2011 § Medtronic – Worldwide Diabetes growth of 8.7% driven by solid international sales § Reata/Abbott – Release positive interim phase 2b results for bardoxolone methyl in CKD § Amylin/JDRF – Announce plans to investigate metreleptin as a treatment of type 1 diabetes Diabetes Close Up #105 ~ January/February 2011 ~ It’s Complicated ~ www.closeconcerns.com 3 § Bioton – Announces plans to partner with Actavis to market its insulin products § CVS Caremark – Plans rollout of pharmacist driven diabetes management initiative § Insulet – Revenue grows 36% and gross margins
Recommended publications
  • Molecular Basis of Blood Glucose Regulation Asma Ahmed and Noman Khalique
    Chapter Molecular Basis of Blood Glucose Regulation Asma Ahmed and Noman Khalique Abstract Blood glucose level is regulated by multiple pancreatic hormones, which regulate it by different pathways in normal and abnormal conditions by expressing or suppressing multiple genes or molecular or cellular targets. Multiple synthetic drugs and therapies are used to cure glucose regulatory problems, while many of them are used to cure other health issues, which arise due to disturbance in blood glucose regulations. Many new approaches are used for the development of phytochemical- based drugs to cure blood glucose regulation problems, and many of the compounds have been isolated and identified to cure insulin resistance or regulate beta cell function or glucose absorption in the guts or GLP-1 homoeostasis or two/more pathways (e.g., either cure hyperglycemia or raise insulin resistance or cure pan- creatic beta cell regeneration or augmentation of GLP-1, production of islet cell, production and increased insulin receptor signaling and insulin secretion or decreased insulin tolerance or gluconeogenesis and insulin-mimetic action or pro- duction of α-glucosidase and α-amylase inhibitor or conserve islet mass or activate protein kinase A (PKA) and extracellular signal regulated kinases (ERK) or activate AMPK and reduce insulin sensitivity or suppress α-glucosidase activity and activate AMPK and downstream molecules or prevents cell death of pancreatic β-cell and activates SIRT1 or lower blood glucose due to their insulin-like chemical structures or decrease lipid peroxidation. Keywords: genes, molecular and cellular targets, hormones, pathways 1. Introduction Blood glucose is regulated by the pancreatic hormones alone or in combination with other endocrine glands and all this is controlled by one or more gene or cellular or molecular targets.
    [Show full text]
  • Johnson & Johnson
    JOHNSON & JOHNSON FORM 10-K (Annual Report) Filed 02/22/13 for the Period Ending 12/30/12 Address ONE JOHNSON & JOHNSON PLZ NEW BRUNSWICK, NJ 08933 Telephone 732-524-2455 CIK 0000200406 Symbol JNJ SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/12 http://www.edgar-online.com © Copyright 2013, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2012 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Inhaled Insulin: the Solution for Suboptimal Diabetes Control?
    I EDITORIALS Inhaled insulin: the solution for suboptimal diabetes control? Stephanie A Amiel Stephanie A Amiel For nearly a century, we have been using insulin to action comparable to human soluble (regular) BSc MD FRCP, treat diabetes. Until recently, that insulin has been insulin rather than fast-acting analogues.10 In trials, RD Lawrence given by injection. In 2006, the first inhaled insulin, Exubera® is only ‘non-inferior’ to conventional (not Professor of Diabetic Exubera®, was licenced for use in Europe. The man- analogue) insulins, the latter not always used in Medicine, King’s ufacturers hoped for a warm welcome – the end of equivalent basal-bolus regimens11–14 and in type 2, College London School of Medicine injections and the dawn of a new era of enthusiastic slightly more effective than adding a second oral insulin takers with perfect diabetic control. The agent in very poorly controlled disease.15,16 It has not Clin Med National Institute for Health and Clinical Excellence been tested against fully flexible analogue regimens. 2007;7:430–2 (NICE) was more cautious and recommend that It is clear that inhaled insulin’s sole advantage over inhaled insulin only be used in the presence of diag- injected insulin is its route of delivery. nosed needle phobia (or severe intractable problems Exubera® has low bioavailability, minor and prob- with injection sites) and should be supervised by dia- ably reversible effects on lung function17 and a nat- betes specialists.1 True needle phobia is rare and ural lack of long-term safety data. Active smoking treatable by standard psychological techniques.2,3 On contraindicates its use because of increased bioavail- the NICE criteria, the market for inhaled insulin may abilty of inhaled insulin,18,19 while absorption may be small indeed.
    [Show full text]
  • SEC Form 10-K Annual Report
    e10vk 10-K 1 y80744e10vk.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 3, 2010 Commission file number 1-3215 JOHNSON & JOHNSON (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State of incorporation) (I.R.S. Employer Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (732) 524-0400 SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT Title of each class Name of each exchange on which registered Common Stock, Par Value $1.00 New York Stock Exchange Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes þ No o Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes o No þ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
    [Show full text]
  • The Un-Design and Design of Insulin: Structural Evolution
    THE UN-DESIGN AND DESIGN OF INSULIN: STRUCTURAL EVOLUTION WITH APPLICATION TO THERAPEUTIC DESIGN By NISCHAY K. REGE Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Department of Biochemistry Dissertation Advisor: Dr. Michael A. Weiss CASE WESTERN RESERVE UNIVERSITY August, 2018 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Nischay K. Rege candidate for the degree of Doctor of Philosophy*. Committee Chair Paul Carey Committee Member Michael Weiss Committee Member Faramarz Ismail-Beigi Committee Member George Dubyak Date of Defense: June 26th, 2018 *We also certify that written approval has been obtained for any proprietary material contained therein. Dedication This thesis is dedicated to my mother, Dipti, whose constant love and faith have never failed, to my father, Kiran, who taught me of the virtue of curiosity, and to my wife, Shipra, whose kindness and companionship have given me enough strength for eight lifetimes. i Table of Contents Dedication ..................................................................................................................................... i Table of Contents ......................................................................................................................... ii List of Tables ............................................................................................................................... v List of Figures ...........................................................................................................................
    [Show full text]
  • Management Liability Focus Johnson & Johnson 1
    Insured Profile Report – Management Liability Focus Johnson_________________________________________________________________________ & Johnson Company Profile Credit Details Location 1 Johnson and Johnson Plz Overall Credit Risk High Risk New Brunswick, NJ www.jnj.com Number of Legal Derogatory 84 Company Type Public Items Liability Amount $322,285.00 Formerly Known As N/A Experian Intelliscore 2.57 SIC Code 2834 SIC Code Description Pharmaceutical Preparations Experian Intelliscore Percentile 2.00 % of companies score lower and have higher credit risk Established 1955 Experian Commercial IntelliscoreSM is an all-industry commercial model using business information to predict business risk. Its Sales (in millions) $65,030.00 predictiveness is among the best on the market today The objective of the Commercial Intelliscore Model is to predict seriously Employees 117,900 derogatory payment behavior. Possible score range from 0 to 100, where 0 is high risk and 100 is low risk Total OSHA Violations 18 -Liability Amount is the total dollar amount of debtor’s legal liability, OSHA is an arm of the Department of Labor that conducts inspections of company including accounts in collection, tax liens,judgments and/or bankruptcies facilities with the goal of preventing work-related injuries, illnesses and deaths. -The Number of Legal Derogatory items are the sum of Tax-Lien Worksites that do not meet health and/or safety standards at the time of inspection may Count, Bankruptcy,Judgment, Collection-Counter and UCC Derog receive an OSHA violation. Total FDA NDC Drugs 177 The total number of FDA Drugs filed in the FDA NDC Drug Database. Business Description Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field.
    [Show full text]
  • Lna 2006 Profiles J.Qxp
    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]
  • Bestccoorporations
    Navoba BUY VETERAN CORPORATE GOVERNMENT FRANCHISE YOUR BIZ COMMUNITY best corporations HUGE CORPORATE for vETERAN-OWNED By Matthew Pavelek CONTRACTING n 1999, the veteran-owned of their way to use VOBs. business movement took In 2007, approximately 10 a giant leap forward with percent of Fortune 1000 companies legislation requiring the sought veteran-owned suppliers. Ifederal government to recognize Through NaVOBA’s efforts, that vetrepreneurs and setting a mandate number has grown by more than OPPORTUNITIES to buy from businesses owned 60 percent. Today, more than 160 by service-disabled veterans. In Fortune 1000 companies maintain 2005, NaVOBA launched Veterans programs designed to use VOBs as Business Journal to bring the VOB preferred vendors in their supplier movement to corporate America. diversity eff orts. While the federal government is Retail colossus Walmart, FOR the world’s single largest purchaser consumer products behemoth of goods and services, the potential Proctor and Gamble, and innovative for vetrepreneurs selling to all of tech giant Apple, Inc. all buy veteran corporate America dwarfs the federal because it’s good business. Johnson opportunity. & Johnson, earning a place among YOUR BUSINESS Unlike the federal government NaVOBA’s Best 10 Corporations for and its prime contractors, many Veteran-Owned Businesses for 2011 states, and some local and municipal and 2012, provides further evidence governments, corporate America is that the VOB movement is advancing NaVOBA is proud to honor the 10 Best Corporationsporations not mandated by law to use veteran- well beyond the beltway. for Veteran-Owned Businesses for 2012. owned suppliers. Just like any Earning the honor as one of business, large corporations exist to NaVOBA’s 10 Best Corporations for turn a profi t.
    [Show full text]
  • Caring for the World . . .One Person at a Time™ Inspires and Unites the People of Johnson & Johnson
    OUR CARING TRANSFORMS 2007 Annual Report Caring for the world . .one person at a time™ inspires and unites the people of Johnson & Johnson. We embrace research and science—bringing innovative ideas, products and services to advance the health and well-being of people. Employees of the Johnson & Johnson Family of Companies work with partners in health care to touch the lives of over a billion people every day, throughout the world. The people in our more than 250 companies come to work each day inspired by their personal knowledge that their caring transforms people’s lives . one person at a time. On the following pages, we invite you to see for yourself. Our Caring Transforms ON THE COVER Johnson & Johnson is founding sponsor and continues to support Safe Kids Worldwide®. For 20 years the organization has grown, now teaching prevention as a way to save children’s lives in 17 countries around the world. In Brazil, Nayra Yara da Paz de Jesus carefully washes her hands, a safe, healthy habit she and other children are learning from a local Safe Kids® program. Find out more in our story on page 22. C H A I R M A N ’ S L E T T E R To Our Shareholders Caring for the health and well-being of people throughout the world is an extraordinary business. It is a business where people are passionate about their work, because it matters. It matters to their families, to their communities and to the world. It is a business filled with tremendous opportunity for leadership and growth in the 21st century; a business where unmet needs still abound and where people around the world WILLIAM C.
    [Show full text]
  • Maikawa STM 2021.Pdf
    SCIENCE TRANSLATIONAL MEDICINE | REVIEW DRUG DEVELOPMENT Copyright © 2021 The Authors, some rights reserved; Engineering biopharmaceutical formulations exclusive licensee American Association to improve diabetes management for the Advancement Caitlin L. Maikawa1, Andrea I. d’Aquino2, Rayhan A. Lal3,4,5, of Science. No claim 4,5 1,2,4,5,6 to original U.S. Bruce A. Buckingham , Eric A. Appel * Government Works Insulin was first isolated almost a century ago, yet commercial formulations of insulin and its analogs for hormone replacement therapy still fall short of appropriately mimicking endogenous glycemic control. Moreover, the controlled delivery of complementary hormones (such as amylin or glucagon) is complicated by instability of the pharmacologic agents and complexity of maintaining multiple infusions. In this review, we highlight the advantages and limitations of recent advances in drug formulation that improve protein stability and pharmacokinetics, prolong drug delivery, or enable alternative dosage forms for the management of diabetes. With controlled delivery, Downloaded from these formulations could improve closed-loop glycemic control. ENGINEERING OPPORTUNITIES TO IMPROVE DIABETES tive treatment with insulin alone is already highly burdensome and MANAGEMENT costly—requiring frequent glucose monitoring, mealtime insulin Over the past century, insulin replacement therapy has been impera- boluses, basal insulin delivery through infusion pumps or long-acting http://stm.sciencemag.org/ tive to saving lives and improving diabetes treatment outcomes. The analogs, and routine carbohydrate counting—and still does not truly administration of exogenous insulin prevents ketoacidosis, which recapitulate the complexities of metabolic control in nondiabetic was once a universally fatal condition. Although insulin has histor- individuals (Fig. 1B) (7).
    [Show full text]
  • FORM 10-Q Johnson & Johnson
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended July 4, 2021 or Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ☐ for the transition period from to Commission file number 1-3215 Johnson & Johnson (Exact name of registrant as specified in its charter) New Jersey 22-1024240 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Johnson & Johnson Plaza New Brunswick, New Jersey 08933 (Address of principal executive offices) Registrant’s telephone number, including area code (732) 524-0400 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
    [Show full text]